Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.

10 Oct 2013

HIV infection heralds worse outcomes in NSCLC

Infection with HIV is an indicator of poor prognosis in patients with non-small-cell lung cancer, analysis of epidemiologic data indicates.

9 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report.

30 Sep 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine.

27 Sep 2013

Study: Antidepressant drugs prove to be effective against SCLC patients

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

27 Sep 2013

Icotinib matches gefitinib in NSCLC second or third line

Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.

26 Sep 2013

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam.

26 Sep 2013

miR-31 in primary tumor cells predicts lymph node metastasis in NSCLC patients

Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question.

25 Sep 2013

Lung cancer patients who received IMRT report less decline in their QOL

An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

Protein pair may be prognostic biomarker for identifying smoking-related lung cancers

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

20 Sep 2013

Current criteria for ALK positive lung cancer needs to be redefined

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.

12 Sep 2013